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ABSTRACT 
 
The World Health Organization defines adverse drug reactions (ADRs) as “a noxious, 
unintended, and undesired effect of a drug that occurs at doses used for prevention, diagnosis, or 
treatment”.  These ADRs can be classified into: type A reactions (60-80%, dose-dependent, 
predictable, and directly related to pharmacology/chemical properties), and type B reactions (20-
40%, usually not dose-dependent, non-predictable). Drug allergic/hypersensitivity reactions are 
antigen-specific immune-mediated type B ADRs. They can be immediate (IgE-mediated; 
“anaphylaxis”) or delayed (IgG- or T cell-mediated). In human medicine, drug allergies are 
estimated to affect 0.1-3% of the general population and up to 15-20% of hospitalized patients. 
Drug hypersensitivity reactions appear similar clinically in dogs and humans, but their exact 
incidence in dogs remains unknown. Little is known about the pathogenesis of drug allergy in 
humans, and even less in veterinary patients. In addition, the literature about drug 
hypersensitivity in animals is very limited and most veterinary curricula spend little time 
covering this clinical issue. 
For the first time in veterinary medicine, this thesis aimed to investigate the awareness of 
veterinarians about drug allergy and its incidence in dogs. To address these goals, we first 
conducted a survey to evaluate the awareness of UIUC graduate veterinarians on the topic. We 
also conducted a retrospective study to determine the incidence and the clinical characteristics of 
drug allergic reactions in dogs seen at a US veterinary teaching hospital over an 11 year-period.   
We designed a survey through SurveyMonkey that targeted UIUC alumni veterinarians 
(n=2164) to evaluate their opinion on drug allergy in veterinary medicine. The results of this 
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survey suggest a lack of awareness and/or knowledge about drug allergic reactions amongst 
veterinarians. Our data further suggests a lack of training in veterinary medical school and a lack 
of information in the literature about veterinary drug allergy. Importantly, the survey also 
highlights the interest of the participants to learn more on the subject.  
We conducted a tiered keyword search of the two clinical medical databases of the UIUC 
veterinary teaching hospital for the past 11 years, and thoroughly reviewed identified cases of 
potential drug HS. The retrospective study is the first to estimate an incidence for drug allergic 
reaction in dogs (0.15%), to report cases of DRESS in dogs (19 cases), and to establish an 
incidence for drug allergic contact dermatitis in dogs (7.7% of all drug allergic reactions). The 
incidence, the clinical pattern, and the drugs involved, matched what has been described in 
human medicine. This study also demonstrated a link between early drug discontinuation and 
prognosis as previously shown in human drug allergy. Importantly, the quality and completeness 
of the medical record were important limiting factors.  
 
Overall, this thesis identified a lack of awareness about drug allergy in veterinary medicine, 
leading to a lack of or delayed recognition of these reactions, often leading to inadequate 
management. This work also confirmed that drug allergic reactions are potentially as frequent in 
dogs as they are in humans, with similar clinical patterns that can be life threatening, and 
therefore represents a significant issue in dogs as well. We therefore believe that improving 
education of veterinarians on the subject could have a significant impact. In the meanwhile, more 
research will be needed to better understand the impact of the drug allergic reactions in 
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veterinary medicine, and eventually create guidelines to improve diagnosis and management of 
these reactions. 
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CHAPTER 1 
INTRODUCTION 
 
Adverse drug reactions – General introduction 
The World Health Organization defines adverse drug reactions (ADRs) as “noxious, unintended, 
and undesired effect of a drug that occurs at doses used for prevention, diagnosis, or treatment”.  
These ADRs can be classified under two types of events.  Type A reactions (60-80%) are dose 
dependent, predictable, and directly related to pharmacology/chemical properties. Type B 
reactions (20-40%) are not dose dependent, non-predictable, and if immune-mediated are called 
“drug hypersensitivity” or “drug allergy.1-8 These later reactions are further separated into two 
categories: immediate (anaphylactic) or delayed reactions. Worldwide, anaphylaxis is often 
defined as "a serious, life-threatening generalize or systemic hypersensitivity reaction" and "a 
serious allergic reaction that is rapid in onset and might cause death."
9,10
 These reactions are 
sometimes called “immediate” because they occur within 24 h of exposure to the allergen, 
usually in the first couple hours.
11,12
  
 
ADR incidence and reporting in human medicine 
In human medicine, the adverse drug reactions are the 4
th
-6
th
 cause of death.
13,14
 They affect 10-
20% of the hospitalized patients and 7% of general population.
4,13,15-18
 The annual cost of these 
reactions, including treatment of the primary reactions, complications, and increased length of 
hospitalization is estimate to $500 billion in the United States.
13,19
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The reporting is based on the filling of ADR reporting forms, historically called “yellow 
cards”. These forms are completed by the clinician in charge of the patient. These forms can be 
completed electronically on the Food and Drug Administration (FDA) website 
(www.fda.gov/Safety/MedWatch/default.htm).  
In addition, pharmaceutical companies include a hotline number on the packaging of their 
drugs in case of questions or comments. Clinicians, but also patients themselves, can use this 
phone number to report an adverse reaction following the administration of the drug in question. 
Pharmaceutical companies compile case on a regular basis and are obligated to share them with 
the necessary governmental agency. 
In Europe, a platform of pharmacovigilance network, called the GA2LEN–ENDA–
DAHD, centralize reports about drug allergic reactions. This network connects the European 
Network for Drug Allergy (ENDA) and the Global Allergy and Asthma European Network 
(GA2LEN) to create the Drug Allergy and Hypersensitivity Database (DAHD).
20
 
 
Veterinary ADR incidence and reporting 
In veterinary medicine, the incidence of ADRs remains to be established. However, similar 
adverse drug reactions to those reported in humans can affect veterinary patients. This is 
especially accurate for Type A reactions because they are linked to properties of the drug that 
usually remain the same between species.  
FDA Center for Veterinary Medicine (FDA_CVM) is the veterinary branch of the FDA. 
The FDA-CVM is in charge of ADR in veterinary patients 
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(www.fda.gov/AnimalVeterinary/default.htm). The reporting of veterinary ADRs to the FDA 
was more recently developed than in human medicine, but the online reporting is similar. 
Reporting is accessible to the public and veterinarians and relies on voluntary reports, with a 
different section devoted to mandatory reporting for manufacturers of veterinary drugs.  
In Australia, the Australian Veterinary Association Adverse Drug Reaction 
Subcommittee (ADRSC) published three ADR report between 1992 and 1996. They used the 
following categories to classify these reactions: 1) “definite” ADR when the ADRSC and 
manufacturer agree that there is no rational explanation other than an ADR for the animal’s 
clinical signs; 2) “probable” ADR when there is insufficient evidence to confirm an ADR, but an 
ADR is more likely than other possibilities and/or cannot be excluded as a possibility; 3) “non-
ADR” when the case is definitely not an ADR, when there is another more likely explanation, or 
when there is not enough information to allow classification; 4) “unclassified” ADR if the 
manufacturer and the Adverse Drug Reaction Subcommittee (ADRSc) disagreed in their 
assessment of the report.
21-23
 
In the UK, the Suspected Adverse Reaction Surveillance Scheme (SARSS) at the 
Veterinary Medicines Directorate (VMD) has been collecting ADR reports in veterinary patients 
since 1989.
24-42
 They publish annual reports that presenting the ADR per species and highly the 
tendency (increase or decrease), as well as the new type of ADR observed with new medication. 
These reports include animal reactions to veterinary drug, environmental exposure, exposure to 
human medications, and also the lack of efficacy of the drugs. The reporting is based on a 
reporting form that can be filled out by the veterinarian, the marketing authorization holders 
(MAHs), the general public and other organizations, such as the Animal Health and Veterinary 
Laboratories Agency (AHVLA) and subsequently sent for review.  
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UK report series show a net increase in ADR reports over the years (Fig. 1). This 
probably reflects an increased awareness among practitioners about this reporting system, and 
also the fact that the European marketing authorization allowed to raise the reporting to an 
international level.
33
 In addition, a European electronic ADR reporting system was set up during 
that period, which has eased the reporting and therefore increased veterinarians’ participation.29 
Finally, caseloads of veterinary practices have increased during these years, which could also 
explain the increase in ADR reports.  
 
Drug allergies 
Types of drug allergy 
Drug hypersensitivity, or drug allergic, reactions are antigen-specific immune-mediated type B 
ADRs.
1-4,6,8,43,44
 These latter reactions can be subdivided into two broad clinical categories: 
immediate (anaphylactic) and delayed reactions.
2,43
 Delayed drug allergic reactions can be 
mediated by either drug-specific IgG antibodies or T lymphocytes.
4,43
 
 
Drug allergy pathophysiology 
Under the Gell & Coombs classification of immune hypersensitivity (Table I), anaphylactic 
reactions are “type I” hypersensitivity events that are mediated by drug-specific IgE 
antibodies.
11,43,45
 These antibodies induce mast cell and basophil degranulation, releasing very 
potent inflammatory molecules locally (e.g. histamine). These ADRs are called “immediate” 
because they occur within 24 hour of drug exposure, often within 2 hours. Delayed drug allergic 
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reactions, on the other end, require multiple days of exposure to the medication before the onset 
of clinical signs (> 5 days, but sometimes months). Importantly, this delay can sometimes be 
shortened to a few hours if the patient has previously been exposed to the drug. Under the Gell & 
Coombs classification of immune hypersensitivity, “delayed” drug allergic reactions belong to 
types II, III (both IgG-mediated) or IV (mediated by cytotoxic T cells).
43,46,47
 This classification 
is used for years, but only a few drug allergic reactions fit under those categories. Drug allergic 
reactions can also be classified in pseudo-allergic reactions, primarily antibody-mediated 
reactions and cell-mediated reactions.
48
  
The exact pathogenesis of drug allergy is still unclear. The requirement for immune 
sensitization is established and explains why an ADR can only be considered as a drug allergy if 
the patient has been exposed to the drug previously if the onset is less than 5 days. How and why 
the immune system becomes sensitized against a small chemical tolerated by most individuals 
remains uncertain. Three main theories exist to address this gap in knowledge
43,49-54
: the Hapten 
Hypothesis, the Danger Theory, and the P-I Concept. In the Hapten Hypothesis, the drug is 
believed to be too small to be immunogenic and therefore requires to first covalently bind to a 
protein. In the Danger concept, the immune response to a drug-derived antigen requires the 
presence of co-stimulatory signals and cytokines. The danger signal might result from chemical, 
physical or viral stress. Finally, in the P-I concept the drug is interacting directly with T-cell 
receptors and MHC molecules, without covalent binding to the receptor and without priming by 
antigen presenting cell. 
 
Drug allergy clinical presentation  
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“Immediate” type I reactions 
“Immediate” drug hypersensitivity is also referred to as drug anaphylaxis or anaphylactic drug 
reactions. They can be defined as ‘‘a severe, potentially fatal, systemic allergic reaction that 
occurs suddenly after contact with an allergy causing substance”.43 These reactions occur within 
24 hours of drug exposure, usually 1 to 2 hours. The clinical presentation includes cutaneous 
signs, such as urticaria and angioedema, bronchospasm, vomiting, diarrhea and/or cardiovascular 
shock. Anaphylactic drug reactions can be life threatening, especially when they evolve towards 
an anaphylactic shock.  
 
“Delayed” reactions 
Delayed drug hypersensitivity reactions occur after 4-12 days after the drug therapy was 
initiated.
55,56
 It is important to note that an earlier onset is possible if the patient has previously 
been exposed the drug. The clinical signs involve the skin,
43,56-59
 with clinical signs as mild as a 
rash but potentially very severe such as Stevens-Johnson Syndrome (SJS) or Toxic Epidermal 
Necrolysis (TEN) which carry a 10-50% risk of death even in modern human medicine.
58,60
 
Blood cells are also common targets of delayed drug allergy: e.g. immune-mediated haemolytic 
anemia (IMHA), immune-mediated thrombocytopenia (“ITP”), or life-threatening 
pancytopenia.
59,61
 The liver can also be affected, sometimes leading to life-threatening hepatitis. 
Interestingly, delayed drug allergic reactions can lead to the development of long-lasting 
autoimmune diseases that will remain even after drug discontinuation: e.g. lupus, pemphigus.
62,63
   
 
DRESS cases (“Drug Rash with Eosinophilia and Systemic Symptoms”) 
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The DRESS syndrome is a severe form of systemic delayed drug allergy with a wide range of 
clinical presentations. The clinical signs can include fever (can be marked), skin lesions (often 
start as a rash), lymphadenopathy, eosinophilia, and internal organ dysfunction (often the 
liver).
64,65
  We used a modified RegiSCAR scale
66
 to identify DRESS cases among our cohort.  
To be included in this category, the case had to match at least 3 of the 5 following criteria: 1) 
suspected immune-mediated drug reaction; 2) skin lesions, that initially started with a rash; 3) 
fever; 4) systemic involvement including internal organs (e.g. adenopathy, hepatitis, nephritis) or 
peripheral lymphadenopathy; and/or 5) blood cell count abnormalities. 
 
Allergic Contact Dermatitis 
Contact dermatitis is an inflammatory response of the skin due to the direct contact between the 
skin and a toxicant.
67
 Like other ADRs, these reactions can be classified as type A or B, but they 
are limited to the skin. Drug allergic contact dermatitis is an immune-mediated type B reaction to 
a drug administered topically on the skin.
67-72
 Contact dermatitis represents approximatively 10% 
of all dermatology visits in human medicine and is thought to represent up to 90-95% of 
occupational skin diseases. Yet, the exact incidence of contact dermatitis is unclear in human 
medicine, and completely unknown in veterinary medicine.
67
  
 
Drug allergy diagnosis 
The diagnosis of drug allergic reactions is mainly based on clinical presentation and recent 
exposure to a drug. Drug challenges can also be used as diagnostic tool and they are considered 
as very reliable.
43,59,73,74
 A dechallenge consists in interrupting the administration of the 
suspected drug to see whether the clinical signs resolve. Afterwards, a rechallenge can be 
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attempted by reintroducing the drug. If the clinical signs reoccur a drug allergy is highly 
suspicious. However, rechallenges can trigger life threatening reactions and are therefore not 
commonly recommended. Yet, these rechallenges can sometimes be performed involuntarily 
during the course of the patient therapy and the thorough review of the therapeutic history is 
primordial.    
 Skin tests to diagnose drug allergic reactions include prick testing, patch testing, and 
intradermal testing.
43
 These tests were developed and validated to test allergic reactions to 
environmental allergens in human patients, such as hay fever. These tests have shown very good 
results with immediate reactions to β-lactam antibiotics in humans, but their reliability appears 
very limited for other types of drug allergic reactions.
43,75-77
  
Ex vivo diagnostic tests, such as the Lymphocyte Transformation Test (LTT), exist, but 
are not widely available. The LTT consists in exposing patients’ leukocytes to the suspected drug 
in vitro and measuring any subsequent drug-induced cell proliferation.
78,79
 Indeed, lymphocytes 
will only proliferate in vitro if they are exposed to the antigen they are sensitized against. The 
LTT has a reported sensitivity of 60-70% and a reported specificity of 85–93%, but these rates 
are significantly increased when patients are properly selected before testing to confirm the 
probability of the reaction (e.g. accurate timeline of events, adequate clinical signs).
78
 
 The use of algorithms in diagnosing ADRs has been described in human medicine.
80
 
These algorithms are more easily used for type A reactions where clinical signs have already 
been clearly established. However, they can be applied to drug allergic reactions as well.
81
 
Specific algorithms have recently been established for drug allergic reactions.
7,20
 They analyse 
the history of the patient (timing, previous exposition), results of diagnostics tests (skin prick 
test, skin intradermal test), and provocation test.  
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Drug allergy management 
The discontinuation of the culprit drug is the keystone component of the treatment.
1,7,43,55,82-84
 
Supportive care is sometimes needed with certain clinical presentations: e.g. topical treatment 
with open skin lesions; blood transfusion with anemia; antihistamines with urticarial; or IV fluids 
with shock. The prognosis will depend a lot on the early recognition of the reaction, the early 
withdrawal of the drug and the target organ.
85
 
 
Drug allergy epidemiology 
Incidence  
In human medicine, the exact incidence of drug allergic reactions is not fully determined as 
studies have usually focused on specific patient populations (e.g. HIV+ patients).
7
 In addition, 
methodologies vary significantly between published reports; some having included reactions 
self-reported by patients while others only included reactions confirmed by a clinician; some 
studies focused on electronic records within one given hospital while others included reports 
from national reporting databases. However, drug hypersensitivity reactions are thought to 
account for 1/3 of all ADRs and are thought to affect 0.2 -3% for the general patient population, 
and potentially up to 15-20% of hospitalized patients.
86-92
 
In veterinary medicine, the incidence of drug allergic reactions has never been investigated. 
However, drug allergy experts believe it is similar to what is observed in humans when 
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considering veterinary patients such as dogs who often receive similar drugs for similar diseases 
than their human counterpart.
43
 
Predisposing factors 
The existence of predisposing factors to drug allergy has never been investigated in veterinary 
medicine. However, there is some evidence suggesting that women might be more commonly 
affected by drug allergy than men.
93-95
 Pre-existing immune disorders, such as asthma and 
systemic lupus erythematosus, appear to increase the risk of drug allergic reactions.
1,96,97
 
Interestingly, infectious diseases, such as chronic viral infections (e.g. herpes and HIV)
98
 or 
recurring bacterial infections (e.g. cystic fibrosis)
99
 seem to also be associated with an increased 
risk of drug allergy that goes beyond increased drug exposure.
100
  
Pharmacovigilance & reporting 
During drug development, clinical trials include relatively small number of patients, decreasing 
the likelihood of observing drug allergic reactions that often have an incidence of 1% or less. 
Post-marketing pharmacovigilance therefore plays a primordial role in tracking drug allergy. 
Yet, to date, none of the ADR reporting systems presented above, properly separate drug allergic 
reactions, limiting their usefulness in the field of drug allergy. 
 
Training, knowledge and awareness about drug allergy among clinicians  
Underreporting and misdiagnosis of drug allergic reactions also affect their clinical 
outcome.
101,102
 Thus, the early recognition of a drug allergic reaction leading to early 
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discontinuation of the culprit drug reaction has specifically been associated with a better 
prognosis in human medicine.
1,7,55,83,84
  
In 1976, Inman discussed these issues in his so-called “seven deadly sins”: 1) 
“complacency”, encouraged by the one-sided drug promotion and belief that only safe drugs are 
allowed on the market; 2) “fear” of possible involvement in litigation or investigation of 
prescribing costs by the Health Departments; 3) “guilt” of having administered the treatment 
which may have harmed a patient; 4) “ambition” to collect and publish a personal series of cases; 
5) “ignorance” of the Committee’s requirements for reporting; 6) “diffidence” about reporting 
mere suspicions; and finally 7) “indifference” on the part of an individual doctor to his/her 
essential role as a clinical investigator who should be contributing to the general advancement of 
medical knowledge.
103
 We and others believe that these sins also apply specifically to drug 
allergy, with an even stronger emphasis on lack of knowledge since these drug reactions 
represent an even smaller proportion of pharmacology teaching than general ADRs in medical 
and veterinary schools. For instance, the lack of knowledge about drug allergy in human 
medicine has been associated with an increased risk of mis- or delayed diagnosis, further leading 
to inappropriate management, increased costs, and decreased prognosis.
104-106
 Inaccuracies in the 
interpretation of drug allergy diagnostic tests have also been documented in surveys about drug 
allergy in human medicine.
104,105
   
 
Concluding remarks & Thesis goals 
Little is known about drug allergy in veterinary medicine. The literature is sparse and the 
incidence of drug allergic reactions remains unknown. For the first time in veterinary medicine 
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to our knowledge, our thesis aimed to investigate the awareness of veterinarians about drug 
allergy and its incidence in veterinary patients. To address these goals, we first conducted a 
survey to evaluate the awareness of UIUC graduate veterinarians on the topic. We also 
conducted a retrospective study to determine the incidence of drug allergy in dogs seen at a US 
veterinary teaching hospital, and to further define the clinical characteristics of these reactions.  
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TABLES 
Table I: Gell & Coombs Classification of Drug Hypersensitivity 
 
IMMUNE 
REACTION 
MECHANISM EXAMPLES OF 
CLINICAL 
MANIFESTATIONS 
TIMING OF 
REACTIONS 
Type I 
(IgE-
mediated) 
IgE mediated mast 
cell degranulation 
Urticaria, angioedema, 
bronchospasm, 
anaphylaxic shock 
<24h 
Type II 
(cytotoxic) 
Ig M/G induced 
cell lysis 
Blood dyscrasia > 5 continuous 
days of exposure 
(shorter at 
reexposure) 
Type III 
(immune 
complex) 
Drug-Ig M/G 
complex 
deposition 
and/or 
complement 
activation 
Arthropathy, nephritis, 
cutaneous vasculitis 
> 5 continuous 
days of exposure 
(shorter at 
reexposure) 
 
Type IV 
(delayed, 
cell-mediated) 
Cytotoxic T cells Allergic contact 
dermatitis, toxic 
epidermal necrolysis, 
hepatitis 
> 5 continuous 
days of exposure 
(shorter at 
reexposure) 
14 
 
Modified from ‘Clinical Aspects of Immunology’47  
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FIGURES  
Figure 1: Increase in ADR reports for dogs over the years in UK. 
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CHAPTER 2 
DRUG ALLERGY SURVEY OF THE ALUMNI OF THE COLLEGE OF 
 VETERINARY MEDICINE AT THE UNIVERSITY OF ILLINOIS. 
 
ABSTRACT  
Drug allergic reactions are immune-mediated adverse drug events: “immediate” IgE-mediated 
(≈1/3) or “delayed” IgG/T cell-mediated reactions. This topic is rarely taught in any detail during 
veterinary training, decreasing clinicians’ awareness and preparedness to diagnose and manage 
these reactions. We therefore designed a survey through SurveyMonkey that targeted UIUC 
alumni veterinarians (n=2164) to evaluate their opinion on this matter. Over 8 weeks, the survey 
received a 12.9% rate. 43.8% of responders believed their curriculum had not prepared them 
adequately to diagnose and treat these reactions; 33.6% indicated that they never received any 
information about drug allergy during their training; and 50.6% that there isn’t enough 
information in the veterinary literature. Yet, 78.3% estimated seeing 1-12 confirmed or highly 
suspicious cases/year, 9.6% 13-24 cases, and 1.7% 25-60 cases. Participants indicated that drug 
allergy usually involves: skin (97.6%), GI (89.2%), respiratory (88.8%), cardiovascular (77.3%), 
and blood (69.3%). Initially, most included clinical signs compatible with anaphylaxis only 
(83.1%), rather than delayed reactions (1.0%) or both (15.9%). However, after reading a short 
informative paragraph about drug allergy, 30.8% participants indicated that they would include 
drug allergy more often in their differential diagnosis and 45.1% that they would start asking 
about past drug allergy. Finally, 87.7% indicated being interested in learning more about drug 
allergy as part of their continuing education in the future. In conclusion, this survey suggests that 
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there might be a lack of awareness secondary to a lack of teaching specific to drug allergy in 
veterinary medicine, like has been identified in human medicine previously. 
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INTRODUCTION 
 
The World Health Organization defines adverse drug reactions (ADRs) as noxious, unintended, 
and undesired effects of a drug that occurs at doses used for prevention, diagnosis, or treatment. 
“Drug hypersensitivity” or “drug allergic” reactions are antigen-specific immune-mediated type 
B ADRs.
1-7
 These latter reactions can be subdivided into two broad clinical categories: 
immediate (anaphylactic) and delayed reactions.
5,8
  
 Little is known about drug allergic reactions in veterinary patients. Most veterinary curricula 
include little training about them. In addition, little literature has been published on the subject in 
veterinary medicine. Drug hypersensitivity reactions in dogs appear to have a similar clinical 
pattern to those reactions seen in humans,
8
 and the little research that has been conducted on the 
pathogenesis of these reactions in this species revealed similar biomarkers.
9-11
  
 In human medicine, the early recognition of the reaction associated with the early 
discontinuation of the suspected drug is associated with a better prognosis.
2,12-15
 Yet, the lack of 
awareness and reporting is still one of the major issues in the prevention, proper diagnosis, and 
treatment of drug allergy, and this significantly affects the estimation of its incidence.
16,17
  
 The present survey was designed to evaluate the awareness towards drug allergy amongst 
veterinarians that graduated from the University of Illinois College of Veterinary Medicine.  
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METHODS 
 
Survey target population 
The survey targeted veterinarians who graduated between 1974 and 2014 form the College of 
veterinary Medicine at the University of Illinois, and who had agreed to be contacted by the 
alumni office for such research or public relation endeavour (n=2164).  
 
Survey format 
This online survey was built within, and sent out by, the SurveyMonkey interface. A personal 
link to the survey was included in the email received by the target population. Participants were 
able to save their answers if they could not finish the all questionnaire in once. The participants 
were not allowed to go backward in the questionnaire. A “skip” option was available for 
questions that were not relevant to the participant. Reminders were sent by email through 
SurveyMonkey. 
 
Survey questions 
The questionnaire was submitted to, and approved by, the University of Illinois Institutional 
Review Board (IRB). The first section of the questionnaire was aimed to define the 
characteristics of the population sample, such age, gender, professional occupation, professional 
location, clinical specialization, research. The second section covered the general knowledge 
about drug allergy, acquired during the veterinary training at UIUC or through readings and 
conferences after graduation. The third section was focused on drug allergy cases that the 
responder sees or used to see in practice: rough incidence, clinical patterns and prevention plan. 
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Mid-survey, a brief informative paragraph about drug allergy (appendix) was introduced before 
some questions were repeated. Finally, the last section inquires about the interest of the 
responder to have more information about drug allergy and their willingness to consult a 
specialist for cases. The entire questionnaire is available by email request to the authors 
(appendix). 
 
Survey pre-testing 
First, we asked some non-veterinarians (n=5) to evaluate the question clarity and the software 
interface. After a few minor modifications of the questionnaire, a beta-test was realized with a 
few veterinarians that were not UIUC alumni (n=12). This led to a few additional minor changes. 
 
Survey management 
The survey was first sent on October 27 2014. Reminders were sent before the survey was 
officially closed 8 weeks later. During the following spring, an email was sent to people with 
active email addresses who did not participate although they did not opt out. This follow-up 
email (pre-approved by the IRB office) aimed to understand what factors could have influenced 
their decision not to participate.  
 
Survey data analysis 
The data were collected from SurveyMonkey in an excel format. Answers to the open questions 
were reviewed and categorized individually. Categorical answers were summarized 
automatically into the SurveyMonkey report.  
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Statistical analysis  
Some descriptive statistics were calculated whenever possible: mean, median, standard 
deviation, range. In addition, an interval-censored life table with a gamma-distribution model 
was used to compare answer series for questions that were asked before and after the informative 
paragraph. P values inferior to 0.05 were considered as the threshold for statistical significance. 
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RESULTS  
 
Response rate 
Survey Monkey reached out to 2164 email addresses provided by the alumni office. Ten people 
had opted out of SuvreyMonkey (in general, not specifically for our survey). In addition, the 
message bounced from 15 email addresses. The survey therefore really reached 2139 persons, 
out of which 275 participated in our survey (12.9 % response rate). Incomplete questionnaires 
were submitted by 37.5% of the responders. 
Our follow-up inquiry to alumni who did not respond is still underway. At this time, 28 
of the 1808 persons contacted replied to this follow-up email. Their responses can be categorized 
as follow: 32.7% did not participate in our survey because they did not feel they had anything to 
say on the topic; 28.6% did not participate in our survey by lack of time; and 10.7% did not 
participate in our survey because they missed the emails. (Table X) 
 
Responders’ characteristics 
Amongst the respondents that indicated their gender (N=268), 66.4% were women and 33.6% 
men. Based on the 242 respondents who indicated their age (88%), their answers ranged from 26 
to 68 years of age (median of 41). 
Of the 254 respondents who indicated their year of graduation, 2001 was the median 
(range: 1974 – 2014), and 36.6 % of the responses came from veterinarians who graduated 
within the last 5 years. Of the 265 participants who indicated their location, 98.9% work(ed) in 
the United States of America, 54% of which in Illinois specifically.  
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Among the 252 respondents who indicated their professional activity, 80.6% are currently 
working as clinicians and 13.1% used to; 24.5% works or worked in academia, 7.1% in industry, 
and 5.6% in a governmental agency. Among the clinicians (N=258), 93.2% work/worked in 
private practice; 79.5% mainly treat/treated dogs and cats, 5.8% horses, 2.7 % exotics and 
wildlife, and 1.6% food animals. Forty-two responders (15.4%) are Board Certified Specialists 
(n=34) or in training (n=3) (Fig 2-A).  Fifty-six responders (19.3%) pursued, or are pursuing a 
degree in research (Fig 2-B).   
 
Training about drug allergy 
When we asked our participants whether they attended a lecture, laboratory, discussion, or 
school seminar about drug allergy during their DVM training at the UIUC College of Veterinary 
Medicine, 29.8% of the 265 answered “yes”, 33.6% “no”, and 36.6% “do not remember”. 
Twenty-six percent of the responders indicated that the information regarding drug allergy in 
their veterinary curriculum was sufficient to diagnose and treat drug allergic reactions with 
confidence, but 43.8% did not and 27.9% did not know.  
Since graduation, 16% of 266 responders mentioned having attended a presentation about 
drug allergy, mainly during a conference (50%), but also continuing education (5%), seminar 
series (5%), residency training (2%), and hospital rounds (2%). Sixty-one percent (N=265) 
indicated having read some articles on drug allergy since graduation. Interestingly, 50.6% of the 
participants (N=265) indicated that the information on drug allergy in the veterinary literature is 
insufficient in their opinion. 
 
Number of cases of drug allergy 
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To the question “How many confirmed or highly suspicious cases of drug allergy do you see per 
year (on average)?”,  10.4% of the participants answered “none”, 78.3% “1 to 12”, 9.6% “13 to 
24”, 1.7% “25 to 60”, and none chose the “>60” option (Fig 3). Interestingly 78 out of the 235 
responders (33.2%) indicated that they would change their answers after reading the informative 
paragraph about drug allergy. Amongst the 76 responders that changed their answers, all 
increased the number of suspected or confirmed cases of drug allergy seen per year (Figure 3), 
leaving us with no  “none”, 51%  of “1 to 12”, 33%  of “13 to 24”, 13%  of “25 to 60”, and 3%  
of “>60”.  The difference in answer profile to this question before and after the informative 
paragraph was statistically significant (P<0.001). 
 
Clinical approach 
To the question “When you take the history of a patient, do you or your technician ask 
specifically whether this patient has any known drug allergy?”, 22.3% of the participants 
(N=238) answered ”never”, 43.7% ”sometimes” , 19.3% “most of the time”, and 14.7% ” 
always” (Fig 4). Interestingly, after reading the informative paragraph, 45.1% of the responders 
(N=233) indicated that they would start asking for previous drug allergy if they did not until 
now. 
When we asked how often the responders usually include drug allergy in their differential 
diagnosis, out of N=241 5.8% chose “never”, 89.6% “sometimes (1-25% of your patients)”, 
3.3% “regularly (26-50% of your patients)”, 1.2% “often (51-75% of your patients)”, and none 
answered “almost always (76-100% of your patients)” or “always (all of their patients)” (Fig 5). 
After reading the informative paragraph, 30.8% of 237 indicated that they would change how 
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often they include drug allergic reactions in their differential diagnosis, 36.7% that they might, 
and 32.5% that they would not. 
When asking if the responders warn/warned owners specifically about the risk of allergic 
reaction to the drugs they prescribed their pet, 13.4% answered “never”, 48.7% “sometimes”, 
28.2% “most of the time”, and 9.7% “always” (N=238). After reading the informative paragraph, 
157 participants modified their responses and the percentages changed to 1.3%, 48.5%, 30.6%, 
and 19.7% “always” (Fig 6).   
We also asked these clinicians whether their medical records include/included a warning 
system if a patient had a history of suspected or confirmed drug allergic reaction (e.g. sticker, 
tag, alert message in the electronic system). Out of the 239 responses, 79.9% were “yes”, 15.1% 
“no”, and 5% “did not know”. 
 
Clinical presentation 
We asked the responders to list the clinical signs that they would associated with a drug allergic 
reaction. When analysing these answers for each responder individually, 83.1% of the responders 
(N=239) indicated only clinical signs matching anaphylaxis (e.g. angioedema, urticaria, 
respiratory distress); 1.0% indicated only clinical signs matching delayed reactions (e.g. 
Erythema Multiforme, Stephen Johnson Syndrome, ITP, IMHA); and 15.9% indicated clinical 
signs compatible with both types of drug allergy (e.g. dermatologic signs, skin eruptions) (figure 
6A, table II-VII). When analysing all the clinical signs given by the responders 41.1% of the 
clinical signs were specific of immediate reactions, 8.1% were specific of delayed reactions, 9.7 
were compatible with immediate and delayed reactions, and  40.5% were relates to any type of 
drug allergy, but to Type A ADR. (Fig 7B). 
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After classification per organ system of each individual answer of the participants, the 
skin was the most commonly cited (100%), followed by the gastrointestinal tract (70.7%), the 
respiratory tract (22.2), the nervous system (31%), and the cardiovascular system (13.4%) (Fig 
8). 
After this open-ended question, we asked participants to select some organ systems that 
may be targeted by a drug allergic reaction from a pre-set list. Out of the 251 persons who 
answered this question, 97.6% selected the skin, 89.2% the gastrointestinal system, 88.8% the 
respiratory system, and 77.3% the cardiovascular system (Fig 8).  
When we asked about the type of blood work abnormalities that the participant might 
associate with a drug allergic reaction, cell blood count abnormalities was the most common 
75.6%, followed by liver enzymes changes 34.9%, and kidney parameters changes 12% (Table 
VIII). Amongst the blood abnormalities, eosinophilia was the most commonly mentioned 
(34.9%), followed by anemia (26.8%), leukocytosis (19.1%), and thrombocytopenia (13.4%) 
(Table IX).  
 
Responder’s wishes 
Among the 252 participants who answered this question, 87.7% indicated being interested in 
learning more about drug allergy as part of their continuing education. When asked which 
method they would prefer for this purpose, they proposed the following options: national or 
regional conferences (63.3%); in-house or university seminars (52.3%); journal articles (62.4%); 
or online (49%; e.g. webinars or Veterinary Internet Network, VIN). Among the 253 participants 
who answered the question, 79.4% indicated that they will consider consulting with an expert on 
drug allergy in the future for specific cases. 
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DISCUSSION 
 
This survey aimed to evaluate the awareness about drug allergy among veterinarians who 
graduated from the College of Veterinary Medicine at the University of Illinois. To our 
knowledge this is the first veterinary survey on drug allergy. 
Our 12.9% response rate is in the low range (9.1-37%) of response rates among the 4 
surveys published in veterinary medicine that did report their response rates (out of 10 veterinary 
surveys indexed in PubMed).
18-21
  Our response rate is also lower than the surveys obtained in 
the 3 published surveys on drug allergy in human medicine (31.8-48%).
22,23
 This relatively low 
rate was probably multifactorial.
24,25
 First, the participation to our survey was voluntary and did 
not have any incentive that could increase the participation rate. However, we specifically 
targeted UIUC alumni to decrease the need for an incentive. In addition, the survey might have 
been too long for clinicians to fill it out at work; 28.6% did not participate in our survey by lack 
of time. However, the format allowed them to save their answers and complete the surveys not 
all at once. It is also possible that the email list provided by the alumni office was not fully up-to-
date. Indeed, these email addresses are updated only on voluntary basis.
24,25
 Interestingly, over 
10% of people who replied to our follow-up email indicated that they missed the emails asking 
them to participate to our survey. Finally, it is possible that the low rate itself shows the lack of 
awareness and/or interest of the veterinarians contacted about drug allergy. Thus, 32.7% of 
people who replied to our follow-up message indicated that they did not participate in our survey 
because they did not feel they had anything to say on the topic. 
The male: female gender ratio among US veterinarians is 0.8 [AVMA website] compared 
to 0.5 in our sample. This difference can be explained by a different gender ratio amongst the 
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UIUC alumni, but for confidentiality reasons, researchers do not have access to the gender 
information of registered alumni. , It is important to note that the gender ratio on the AVMA 
website is only based on employed veterinarian while our survey also included retired 
veterinarians.   
The proportion of board-certified specialists among the US veterinarians is 11.5% 
[AVMA website] against 15.4% in our sample, which is not statistically different. This could be 
relevant because residency programs preparing veterinarians for board examinations likely 
increase the opportunities for these clinicians to learn about drug allergy. 
Our sample includes a significantly higher percentage of clinicians working in private 
practice (93.2%) compared to US veterinarians (60.0%, 2014; P<0.0001). [AVMA website] 
Amongst the responders working as clinicians, most worked with dogs and cats (79.4%), which 
is similar to the general US veterinary population (75.1%,) [AVMA website] This could be 
relevant because most of the studies about veterinary drug allergy were about dogs and cat.
8,26,27
 
Small animal practitioners might therefore be more likely to have read on the subject.  
Only 26% of our responders felt that the information provided during their training about 
drug allergy was sufficient to recognize and treat these cases. Only 1/3 of the participants 
remember having attended a lecture, laboratory, discussion, or school seminar, about drug 
allergy during their DVM training at the UIUC College of Veterinary Medicine. This observation 
can most likely be extended, indeed the AVMA regulates the curriculum in all US veterinary 
schools, and they do not require of the coverage of drug allergy into any detail 
(https://www.avma.org/ProfessionalDevelopment/Education/Accreditation/Colleges/Pages/coe-
pp-requirements-of-accredited-college.aspx). Interestingly, a third of our responders (31.5%) 
graduated within the last 5 years, which coincides with the arrival of a drug allergy specialist at 
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UIUC. These responders may have been more sensitive to the topic because they were more 
exposed to it during their training, through lectures, electives, or research seminars. In human 
medicine studies have shown that the lack education on drug allergy delays their diagnosis and 
treatments.
22,28
 It is important to note that, in the US, the AVMA regulates the material taught in 
all certified veterinary schools. To date, they do not require for drug allergy to be covered.   
Only 16% of our survey responders have apparently attended a presentation on drug 
allergy since graduation. This can be explained by the very limited number of experts in 
veterinary drug allergy. The topic is discussed annually at non-veterinary conferences like the 
Society of Toxicology (SOT) meeting. It even has its own international meeting: Drug 
Hypersensitivity Meeting (DHM) since 2004. However, drug allergies are rarely discussed at 
conferences more commonly attended by veterinarians, even less so at meetings targeting 
general practitioners. The responders would be interested to learn more about drug allergy during 
national or regional conferences (63.3%); in-house or university seminars (52.3%).  
In human medicine, a survey specifically looked at the impact of an educational program 
focused on drug allergy (penicillin) on their clinical management in the US.
22
 Clinicians were 
surveyed 6 week after an educational initiative and the implementation of clinical guideline for 
the cases of drug allergy. They found that the clinicians had a better understanding of how to use 
and interpret the diagnostic tests after the presentation, therefore the diagnostics were more 
accurate as well as the management of the drug allergy cases. They conclude that the increase of 
knowledge and the guidelines were beneficial for the practice.  
Half of the responders (50.6%) thought that the information about drug allergy in the 
veterinary literature is insufficient. Indeed, when searching PubMed, only 19 (12 case reports, 2 
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primary research articles, and 4 reviews) can be.
8,26,27,29-42
 The majority of the participants 
(62.4%)  indicated being interested in learning more about drug allergy by in journal articles.  
Interestingly, after our short informative paragraph about drug allergy, the estimated 
number of drug allergy cases seen per year significantly increased (Fig.2). This illustrates that 
personal knowledge about drug allergy can affect how a veterinarian estimate its importance in 
his/her own practice, linking lack of knowledge and underestimation. This also suggests that a 
significant number of these veterinarians might have misdiagnosed some cases of drug allergy in 
the past. 
After reading this informative paragraph, multiple participants also indicated that they 
would start asking for previous drug allergic reactions when taking the history and warning the 
owners about drug allergy when prescribing a drug (Fig 4 & 5). Multiple responders also 
indicated that they would change how often they would include drug allergy in their differential 
diagnosis (Fig 6). This further illustrates that improving education on drug allergy could improve 
their prevention and/or their recognition.  
The majority of responders (≈70%) described clinical signs associated with immediate 
reactions, such as cutaneous signs (angioedema or urticarial), respiratory distress, or gastro-
intestinal signs. Yet, in human medicine, immediate reactions represent only 30-40% of drug 
allergic reactions.
3,8,43-48
 Only 16.9% of responders mentioned clinical sings that can be 
associated with delayed reactions: 7.1% mentioning skin lesions associated with delayed reaction 
(e.g. erythema multiforme, toxic epidermal necrolysis), 5.9% blood cell abnormalities, and 2.9% 
liver problems (Fig 7A). Yet, these reactions are the most common drug allergic events in human 
medicine.
3,8,43-48
 Importantly, 40.5% of the clinical signs listed by the respondents are 
characteristic of dose-dependent type A ADR (e.g. vomiting, ataxia) and are rarely seen with 
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drug allergy (Fig 7B).  These results illustrate that a significant number of veterinarians confused 
dose-dependent direct drug toxicity and drug allergy, and that the majority of responders mainly 
(if not even exclusively for some of them) consider immediate reactions when thinking about 
drug allergy. 
This could be the consequence of the lack of training reported by our participants. This 
could lead to a significant risk of misdiagnosing these reactions
22,28,49
 and poorer outcome,
16,17
  
as previously shown in human medicine.  
At the end of the survey, 79.4% of the 252 participants expressed the desire to learn more 
about drug allergy. This support the participants’ opinion at the beginning of the survey, that 
they felt inadequately prepared to recognize and treat drug allergic reactions.  
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CONCLUSION 
 
For the first time in veterinary medicine to our knowledge, veterinarians were surveyed about 
their awareness on the subject of drug allergy. The results of this survey suggest a lack of 
awareness and/or knowledge about drug allergic reactions amongst veterinarians. Our data 
further suggests a lack of training in veterinary medical school and a lack of information in the 
literature about veterinary drug allergy. Importantly, the survey also highlights the interest of the 
participants to learn more on the subject. Yet, a larger survey will be required in order to confirm 
and refine these suggested conclusions. Such survey would include veterinarians from different 
US veterinary schools with refined questions based on weaknesses discovered when analyzing 
this pilot survey. 
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TABLES                
Table II: Categories of clinical signs that responders associate with drug allergy 
Clinical signs n (%) 
Skin & mucosal skin junctions 472 (44.7%) 
GI  312 (29.5%) 
Behavior and neurological system 85 (8.0%) 
Respiratory tract 58 (5.5%) 
Cardiovascular 54 (5.1%) 
Fever 32 (3.0%) 
Blood cell abnormalities 14 (1.3%) 
Eyes  8 (0.8%) 
Liver 7 (0.7%) 
Kidney 5 (0.5%) 
Death 5 (0.5%) 
Joints 4 (0.4%) 
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Table III: Details of all the clinical signs affecting the skin and mucocutaenous junctions 
(including ears and eyes) 
Clinical Signs n (%) 
urticaria , hives, severe hives, mild hives, wheals,  rashes, skin rash 175 (37.1%) 
angioedema,  swollen face, swelling of face/muzzle, facial edema, 
angioneurotic edema,  facial swelling, subcutaneous edema, swollen 
muzzle, swelling 93 (19.7%) 
pruritus, prurit 43 (9.1%) 
skin/cutaneous reaction, skin/cutaneous/dermatological  lesions, 
skin/dermatologic change/action, dermatologic/dermatological 
manigestation, dermatopathy, dermatologic evidence, cutaneous/derm 
signs, skin problem/disorder,, abnormal skin, skin manifestation 41 (8.7%) 
erythema, severe erythema, erythema of skin, skin erythema,  skin 
redness, annular erythemic lesions 22 (4.7%) 
papule, vesicule, skin eruption  21 (4.4%) 
itching, itch, itchiness 17 (1.5%) 
steven Johnson syndrome, toxic epidermal necrolysis, sloughing of the 
skin, sloughing tissue, peeling of the skin, skin necrosis, erythema 
multiforme,  mucosal sloughing 15 (1.0%) 
vasculitis 8 (1.7%) 
dermatitis/ skin inflammation 8 (1.7%) 
contact reaction, local dermatological reaction if topical medication, 6 (1.3%) 
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injection site reaction/inflammation, contact allergy, local reaction of 
administration site  
dry eyes, decrease tears production, kcs 6 (1.3%) 
conjonctival erythema, conjunctival hyperemia, red eyes, peri-ocular 
blepharitis, peri-ocular dermatitis, peri-ocular swelling 6 (1.3%) 
Skin/dermal ulceration, oral ulceration 6 (1.3%) 
alopecia/hair loss 5 (1.1%) 
 
 
  
48 
 
Table IV: Details of digestive signs (including the liver) 
Clinical Signs n (%) 
vomiting, nausea 140 (44.9%) 
diarrhea, colic 113 (36.2%) 
gastro-intestinal signs/issues/upset/disturbance/symptoms  32 (10.3%) 
anorexia, inappetence, decrease appetite. lack of appetite 19 (6.1%) 
hepatopathy, liver, hepatic necrosis, increase liver enzymes, liver 
failure, liver reaction 8 (2.6%) 
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Table V: Details of behavioural and neurological signs 
Clinical Signs n (%) 
lethargy, depression, weakness, malaise 42 (49.4%) 
neuro signs,  neurologic,  neurological manifestation,  neuro problem 17 (20.0%) 
seizure, tremor, trembling, muscle tremor, jerky movements, ataxia 11 (12.9%) 
behavioral changes   5 (5.9%) 
hyperactivity, hyperexcitability, agitation, anxiety, restlesness 5 (5.9%) 
ataxia 5 (5.9%) 
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Table VI: Details of respiratory signs  
Clinical Signs n (%) 
respiratory distress, dyspnea, trouble breathing, respiratory 
difficulties/labored respiration, difficulty breathing 42 (72.4%) 
respiratory/respiratory signs, respiratory abnormalities 6 (10.3%) 
tachypnea/rapid respiration 5 (8.6%) 
swelling airways, laryngeal edema, pharyngeal edema, swelling of the 
pharynx/larynx, tongue swelling  5 (8.6%) 
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Table VII: Details of cardiovascular signs 
Clinical Signs n (%) 
collapse,  acute collapse, circulatory collapse, cardiovascular collapse  15 (27.8%) 
hypotension, paleness, pales mucous membranes, palor 15 (27.8%) 
shock, anaphylactic shock 8 (14.8%) 
Tachycardia, bradycardia  6 (11.1%) 
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Table VIII: Biochemistry abnormalities associated with drug allergic reaction by the responders. 
Blood work abnormalities n (%) 
Liver 73 (54.9%) 
Kidney 25 (18.8%) 
Proteins (Total Protein, albumin and globulines) 16 (4.5%) 
Electrolytes 7 (5.3%) 
Dehydration 4 (3.0%) 
Glycemia 3 (2.3%) 
Blood gases 3 (2.3%) 
Pancreas 2 (1.5%) 
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Table IX: Blood cell count abnormalities (n=158) 
Blood cell lines n (%) Abnormalities Answers n 
Red blood cells 65 (24.7 %) Decrease 56 
  Increase  5 
  Not specified 4 
Platelets 32 (12.2 %) Decrease 28 
  Increase  2 
  Not specified 2 
White blood cells 69 (26.2 %) Decrease 8 
  Increase  40 
  Not specified 21 
Eosinophils 75  (28.5%) Increase 73 
  Not specified 2 
Neutrophils 14 (5.3 %) Decrease 2 
  Increase 12 
Lymphocytes  3 (1.1 %) Decrease 2 
  Increase 1 
Basophils 2 (0.8%) Increase 2 
Mast cells 1 (0.4%) Increase 1 
Monocytes 1 (0.4%) Increase 1 
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Table X: Reason why the veterinarian did not take the survey. 
Reasons why the survey was not completed n (%) 
lack of time 8 (28.6%) 
nothing to say about the topic  9 (32.1%) 
missed the emails  3 (10.7%) 
no interest on the topic 1 (3.6%) 
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FIGURE LEGENDS 
Figure 2: Professional training level of the responders. 
Panel A presents the distribution of board training and/or certification, and panel B of research 
training and degrees, among the survey participants. 
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Figure 3:  Rough estimate of drug allergy incidence in the responder’s practice. 
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Figure 4: Inquiring for previous history of drug allergic reaction while taking the history of the 
patients. 
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Figure 5: Warning about the risk of allergic drug reaction when prescribing medication. 
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Figure 6: Frequency of “drug allergy” inclusion into the differential diagnosis. 
 
  
60 
 
Figure 7: Types of reaction describe by the clinical signs given by the responders. 
Panel A presents the percentage of clinical signs given by the responders that can be associated 
with immediate or delayed drug allergic reactions. Panel B presents the categories of clinical 
signs associated with drug allergic reactions by the responders. 
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Figure 8: Organ systems associated with drug allergic reactions by the responders. 
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CHAPTER 3 
A RETROSPECTIVE STUDY ON DRUG ALLERGIC REACTIONS 
SEEN AT A US VETERINARY TEACHING HOSPITAL. 
 
ABSTRACT 
Drug allergic/hypersensitivity reactions are antigen-specific immune-mediated adverse drug 
reactions.  They can be immediate (IgE-mediated) or delayed (IgG- or T cell-mediated). In 
human medicine, they are estimated to affect 0.1-3% of the general population and up to 7% of 
hospitalized patients. The dog has been proposed as a potential animal model to study drug HS. 
Indeed, drug hypersensitivity reactions appear similar clinically in dogs and humans, but their 
exact incidence in dogs remains unknown. Therefore, his retrospective study aimed to estimate 
the incidence and characterize drug HS reactions in dogs seen at the state veterinary teaching 
hospital during the past 11 years. We conducted a tiered keyword search of the two clinical 
medical databases and thoroughly reviewed identified cases of potential drug HS. This approach 
led to 65 cases (1 immediate and 55 delayed reactions), suggesting an incidence of 0.15%. The 
suspected drug was an antibiotic in 58.4% cases, an antiparasitic in 43.1%cases, an NSAID in 
12.3% cases, a barbiturate in 10.8% cases, and an opioid in 10.8% cases, but. 46.9% of these 
dogs were on multiple drugs at the time of the reaction. Delayed reactions involved the skin 
(61.8%), blood cells (47.3%), or the liver (23.6%), but multiple organs were affected in 32.7% 
cases. Hospitalization was required in 30% (n=3) of immediate reactions and lasted from 12 to 
48 hours in these case (median 24 hour); none of these patients died from their drug allergic 
reaction. Hospitalization was required in 42.3% (n=26) of the delayed reactions, with a duration 
that ranged from 12 hours to 12 days (median 3.0 days) Eight cases (14.5%) did not survive their 
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drug allergic reaction, all of which were delayed reactions. Three patients (with delayed 
reactions) were maintained on the drug after a drug allergic reaction had been suspected.  The 
state of all 3 patients worsened, eventually leading to the dogs’ euthanasia. 19 cases matched the 
definition of DRESS (Acronym of Drug Rash with Eosinophilia and Systemic Symptoms) and 
five cases matched the definition of allergic contact dermatitis. 
  
 70 
 
INTRODUCTION 
 
Adverse Drug Reactions (ADR) can be classified into Type A (dose dependent, predictable, and 
directly related to pharmacology/chemical properties) and Type B reactions (not dose dependent, 
non-predictable). Immune-mediated Type B reactions are called “drug hypersensitivity” or “drug 
allergy”, and can be categorized into immediate (anaphylactic) or delayed reactions.1-8 In human 
medicine, drug hypersensitivity reactions are thought to account for 1/3 of all ADRs and are 
thought to affect 0.2 -3% for the general patient population, and potentially up to 15-20% of 
hospitalized patients.
9-15
 In veterinary medicine, the incidence of drug allergic reactions in 
unknown amongst species.  
 A drug allergic reaction requires the sensitization of the immune system against the 
culprit drug, which represents the antigen in this immune reaction. A period of minimum 4-5 
days is required for the immune system to mount a response against a new antigen. This is why 
delayed reactions required at least 4-5 days of drug exposure before the onset of clinical signs, 
unless the patients was previously exposed to the drug.
16,17
 Immediate drug allergic reactions 
occur within 24 hours of drug exposure, usually 1 to 2 hours, but the original sensitization 
required several days of exposure or repeated exposure prior to the first episode of reaction. 
Clinical presentations of such immediate reactions usually include cutaneous signs, such as 
urticaria or angioedema, bronchospasm, and sometimes vomiting, diarrhea or cardiovascular 
shock. Anaphylactic drug reactions can be life threatening when they obstruct airways or lead to 
an anaphylactic shock.  
Clinical signs observed during “delayed” drug allergy commonly involve the skin,6,17-20 
with clinical signs as mild as a rash but potentially very severe such as Stevens-Johnson 
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Syndrome (SJS) or Toxic Epidermal Necrolysis (TEN) which carry a 10-50% risk of death even 
in modern human medicine.
20,21
 Blood cells are also common targets of delayed drug allergy: 
e.g. immune-mediated haemolytic anemia (IMHA), immune-mediated thrombocytopenia 
(“ITP”), or life-threatening pancytopenia.19,22 The liver can also be affected, sometimes leading 
to life-threatening hepatitis. 
In any case, the diagnosis of drug allergic reactions is mainly based on clinical 
presentation and recent exposure to a drug. Drug challenges can also be used as diagnostic tool 
and they are considered as very reliable.
6,19,23,24
 A dechallenge consists in interrupting the 
administration of the suspected drug to see whether the clinical signs resolve. Afterwards, a 
rechallenge can be attempted by reintroducing the drug. If the clinical signs reoccur a drug 
allergy is highly suspicious. However, rechallenges can trigger life threatening reactions and are 
therefore not commonly recommended. Yet, these rechallenges can sometimes be performed 
involuntarily during the course of the patient therapy and the thorough review of the therapeutic 
history is primordial. 
The use of algorithms in diagnosing ADRs has been described in human medicine.
25
 
These algorithms are more easily used for type A reactions where clinical signs of direct toxicity 
have already been clearly established. However, these algorithms can be applied to drug allergic 
reactions as well
26
 More recently, specific algorithms have been established for drug allergic 
reactions.
27,28
 They put more emphasis on the history of the patient (e.g. timing, previous 
exposure), results of diagnostic tests more specific to immune-mediated reactions (skin prick 
test, skin intradermal test), and provocation tests (“rechallenges”).  
The discontinuation of the culprit drug is the keystone component of the treatment.
1,6,16,28-
30
 Supportive care is sometimes needed with certain clinical presentations: e.g. topical treatment 
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with open skin lesions; blood transfusion with anemia; antihistamines with urticarial; or IV fluids 
with shock. The prognosis will depend a lot on the early recognition of the reaction, the early 
withdrawal of the drug, and the reaction’s target organ.31 
Our primary goal was to estimate the incidence of drug allergic reactions in dogs seen at 
the University of Illinois veterinary teaching hospital, using its medical archives. We also aimed 
to further characterize these drug allergic reactions: drugs involved clinical pattern, diagnosis, 
management, outcome, and reporting. 
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METHODS 
 
Search approach 
We searched two electronic databases of the UIUC veterinary teaching hospital (VTH): VetStar 
that is used to archive medical record documents; VAD that is more specifically used by the 
diagnostic laboratory to archive laboratory results. Both databases were searched for dog cases in 
the period of January 1
th
 2003 till April 28
th
 2014 (approximately 11 years). 
 These searches were based on a 3 tier-keyword approach. In tier 1, we used keywords that 
are specific to drug allergy: drug hypersensitivity, drug allergy, drug allergic reaction, adverse 
drug events/reactions, drug reaction, and adverse reaction. In tier 2, we used clinical terms that 
are commonly associated with drug allergy, but also with other pathologies: anaphylaxis, 
anaphylactic reaction/shock, angioedema, urticaria, Erythema Mutliforme, Steven-Johnson 
syndrome, Toxic Epidermal Necrolysis, face swelling, swollen face, nose swelling, and swollen 
nose. Finally, tier 3 terms included clinical descriptors where drug allergy is a possible, but not 
frequent diagnosis: arthropathy, polyarthropathy, IMHA, ITP, Evens syndrome, aplastic anemia, 
autoimmune disease, discoid lupus erythematous, and lupus erythematous. Additionally, the 
searches in VAD included some keywords that were more specific to laboratory diagnostic tests 
(Table I): e.g. lymphopenia for complete blood count; eosinophilic hepatitis or immune-mediated 
nephritis for organ biopsy and cytology. Finally, we also investigated 30 specific VTH cases for 
which Dr. Lavergne had been consulted during the previous 5 years because of a suspicion of 
drug allergic reaction. The 3 lists of cases were then merged and the duplicates were removed. 
 
Exclusion criteria 
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We excluded the cases with medical records on microfilms. We did not include patients that had 
a history of drug allergy, but were not treated for it the VTH. We excluded cases where a 
diagnosis different than drug allergy was confirmed beyond reasonable doubt. Finally, we 
eliminated cases where the lack of information in the medical record prevented from applying a 
reliable reasoning on the likelihood of a drug allergic reaction. 
 
Inclusion criteria 
To be included in the study, the following criteria had to be met: The patient had to be on the 
drug for more than 5 days before the reactions, if less than 5 days, the patient had to have a 
previous exposure to the drug. The clinical signs had to be compatible with an immune reaction. 
The clinical signs resolved when the drug is discontinued (dechallenge) and/or reoccur when the 
patient was put back on the drug (rechallenge). 
 
Likelihood of a drug allergic reaction 
The likelihood of the drug allergic reaction was categorized as “likely” or “possible”. A case was 
considered “likely” if clinical and circumstantial evidence pointed towards drug allergy as the 
most likely diagnosis. A case was considered “possible” when the available information 
supported the possibility of a drug allergic reaction without eliminating other etiologies. 
 
DRESS cases (“Drug Rash with Eosinophilia and Systemic Symptoms”) 
The DRESS syndrome is a severe form of systemic delayed drug allergy with a wide range of 
clinical presentations. The clinical signs can include fever (can be marked), skin lesions (often 
start as a rash), lymphadenopathy, eosinophilia, and internal organ dysfunction (often the 
 75 
 
liver).
32,33
  We used a modified RegiSCAR scale
34
 to identify DRESS cases among our cohort.  
To be included in this category, the case had to match at least 3 of the 5 following criteria: 1) 
suspected immune-mediated drug reaction, 2) skin lesions, that initially started with a rash 3) 
fever, 4) systemic involvement including internal organs (e.g. adenopathy, hepatitis, nephritis) or 
peripheral lymphadenopathy, and/or 5) blood cell count abnormalities. 
 
Allergic Contact Dermatitis 
Allergic contact dermatitis is an allergic reaction to a drug administered topically on the skin.
35-38
  
These reactions are limited to the skin, and can be extensive. 
 
Statistical analysis 
Descriptive statistics were used to summarize the data: mean and standard deviation or median 
and range.  
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RESULTS 
 
Case attrition via the step-by-step review process (Fig.9) 
When combining the search lists from the VTH, VDL and consulting cases, 25,127 medical 
numbers where collected. After removal of all the duplicates, a total of 11,643 cases were left for 
review. The first screening aimed to eliminate cases not relevant for our study. Indeed, due to the 
unspecific keywords (tiers 3) for the searches, cases unrelated were present in the listing. For 
example, when using facial swelling for the search, a majority of facial trauma and dentistry 
cases were identified. Also, the services of dentistry, orthopedic surgery, oncology, and primary 
care, include a general warning for drug allergic reaction in their discharge letter.  At end of the 
first screening, 2000 cases were selected for an in depth- review by a veterinarian to eliminate 
cases based on the previously described inclusion and exclusion criteria. The remaining 106 
potential cases were then reviewed by a specialist in drug allergy to determine the likelihood of 
the drug allergic reaction. Sixty-five cases were finally selected for our detailed analysis and 
further characterization. 
 
Incidence 
During our study period (≈11 years), 44,531 dogs were seen at the UIUC VTH and we identified 
65 “likely” or “possible” cases of drug allergy. This would estimate the incidence of drug 
allergic reactions around 0.15%. 
Amongst the 65 cases, 55 were “delayed” reactions (83.3%). Amongst the 55 delayed 
reactions, 43 were categorized has likely (78.2%) and 12 as possible (21.8%). For 83.7% of the 
former cases, a drug allergy was suspected or discussed in the medical record. A differential 
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diagnosis was not found in the chart 61.5% of the cases. For 41.7% of the latter cases, a drug 
allergy was suspected or discussed in the medical record.  Eleven of the 66 identified cases were 
“immediate” reactions (16.7%). Amongst these 10 cases, 5 were categorized has “likely” (50%) 
and 5 as “possible” (50%). For 60% of the former cases, a drug allergy was suspected or 
discussed in the medical record. For none of the latter cases, a drug allergy was suspected or 
discussed in the medical record. 
 
Case population description (Table XII) 
The gender ratio in our selected cases was 1:1. The most common breeds were mixed breed dog 
(26.2%), labrador retriever (10.8%), shih tzu (6.2%), american pit bull terrier (4.6%), maltese 
(4.6%), pug (4.6%), shetland sheepdog (4.6%), chihuahua (3.1%), cocker spaniel (3.1%), german 
shepherd dog (3.1%), pomeranian (3.1%), and vizsla (3.1%). 
 
Onset of the reaction 
The time between when the suspected drug was first started and the onset of the clinical signs 
was clearly established for 23 cases (35.4 %; 4 immediate and 29 delayed reactions). 
The onset ranged from 1 to 5 hours (median 1.5 hour) for immediate reactions and from 1 
day to 44 months (median 7 days) for delayed reactions. Importantly, the 5 patients affected by a 
delayed drug allergy that started less than 5 days after drug exposure started, had been exposed 
to the culprit drug previously. Interestingly, the median onset was 8 months (4 days-44 months) 
for phenobarbital. For 42 cases (64.6 %; 6 immediate and 26 delayed reactions), we could not 
establish the delay between first drug dose and reaction onset beyond the fact that the animal had 
been receiving the medication for at least 5 days.  
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Clinical presentation 
Amongst the immediate reactions, 90% involved the skin (Fig 10-A). The remaining case 
involved the gastrointestinal and cariovascular system. The most frequent cutaneous signs 
amongst these reactions were urticaria (50.0%), angioedema (50.0%), and pruritus (20.0%). 
Thirty % of these patients displayed a combination of 2 or 3 clinical signs (e.g. urticaria and 
angioedema; urticaria, angioedema, and pruritus). 
Amongst the delayed reactions, the organ system that was the most commonly affected 
was the skin (61.8%), followed by blood cells (47.3%), and the liver (23.6%) (Fig 10-B1). The 
two most commonly affected blood cell lines were red blood cells (34.6% of cases with blood 
dyscrasias) and platelets (12.8%). Blood dyscrasia affecting all blood cell lines (pancytopenia, 
aplastic anemia) represented 5.5% of blood cell cases (Fig 10-B2). Multiple organs were affected 
in 32.7% of the delayed reactions: skin & blood (2 cases); skin & liver (3 cases); blood & liver (4 
cases); skin & blood & liver (5 cases). 
 
Severity of the reactions 
Hospitalization was required in 30% (n=3) of immediate reactions and lasted from 12 to 48 hours 
in these case (median 24 hour) (Table XIII). Two of these patients were in shock at presentation 
and all had cutaneous signs. Importantly, none of these patients died from their drug allergic 
reaction. 
Hospitalization was required in 42.3% (n=26) of the delayed reactions, with a duration 
that ranged from 12 hours to 12 days (median 3.0 days) (Table XIII). Amongst these 
hospitalization, clinical signs involved blood cell lines in 34.5% of cases, the skin in 10.9% of 
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cases, and the liver in 9.0% of cases. Eight cases (14.5%) did not survive their drug allergic 
reaction, all of which were delayed reactions. Six were euthanized (75%) and 2 (25%) died 
naturally. Seven of these patients had required to be hospitalized (87.5%). In the survivor group, 
48.9% were characterized as “improved” in the discharge, 31.9% as “unchanged”, and there was 
no information about the patient’s status at discharge in 19.2% unknown (14.9% “undetermined” 
status option in the discharge and  4.3% without any information available).  
Interestingly, three patients (with delayed reactions) were maintained on the drug after a 
drug allergic reaction had been suspected.  The state of all 3 patients worsened, eventually 
leading to the dogs’ euthanasia.  
 
Suspected drugs 
Almost half of the patients (46.9 %) were on multiple drugs when they developed their drug 
allergic reaction. The classes of drug suspected for all the reactions included are detailed in 
Tables XIV. The main classes of drug suspected for the delayed reactions include antibiotics 
(55.5%), antiparasitics (41.8%), non-steroidal anti-inflammatory (12.7%), topicals (12.7%), 
steroids (12.7%), barbiturics (12.7%), H1 antagonists (7.3%), opioids (5.4%), thyroid 
supplements (3.6%), azole antifungals (3.6%), antiemetics (3.6%), and ears medication (3.6%). 
 
DRESS cases 
Nineteen cases matched the criteria of DRESS (34.5% of delayed reactions). The estimated 
incidence is 0.04%.  Table II and III compare the characteristics of these patients with the other 
cases. Almost half these patients (47.4%) required a hospitalization. Table IV indicates the drugs 
involved in these cases. Amongst these 19 DRESS cases, 68.4% were categorized as “likely” and 
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31.6% as “possible”. The possibility of a drug allergy was discussed in the medical record in 
92.3% of the “likely” DRESS cases, and 50 % of the “possible” ones. One patient was kept on 
the drug suspected being the trigger of the reaction; the same patient did not survive. The timing 
between the beginning of medication and the reaction was identifiable for 52.6% of the DRESS 
cases, ranging from 2 days to 1 year (median 4.5 days).  
 
Allergic Contact Dermatitis 
Amongst the delayed reactions. 5 cases matched the definition of allergic contact dermatitis (4 
“likely” and 1 “possible”). The estimated incidence is of 0.01%.  Table I compares the 
characteristics of these patients with the other cases. No hospitalization was required in these and 
they all survived the drug reaction. All the drug suspected in these contact dermatitis cases were 
topical flea and tick preventatives (Table XIV). For 100% of the “likely” contact dermatitis 
identified, a drug allergy was discussed in the medical record.  For the “possible” case, a drug 
allergy was not suspected. 
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DISCUSSION 
 
The goal of our study was to estimate the incidence of drug allergic reaction amongst the dog 
population seen at the VTH. We were also interested in characterizing the clinical pattern 
(timing, clinical signs, severity, and outcome) and the suspected drugs.  
The incidence of 0.15% we found in our study is in the lower range of what has been 
reported in human medicine.
9-11
 This was the first attempt at estimating the incidence of drug 
allergy in veterinary medicine that did not focus on one given class of drug. Governmental 
reporting systems have never reported on drug allergic reactions either. Thus, we cannot 
compare our incidence to any previous reports. However, we suspect that it is underestimated, 
mainly due to the lack of awareness from clinicians often associated with a lack of important 
information in the medical record to allow for suspect cases to be included.  It is important to 
note that the dogs seen at our veterinary teaching hospital are not frequently hospitalized. So the 
real incidence of drug allergy in our dog patients should not be compared to the incidence 
reported in human hospitals. 
Interestingly, we reviewed in depth approximately 2000 potential cases, but about 40% of 
the cases had to be put aside because some key information was missing. A thorough review of 
the past history is critical to diagnosis a drug allergy. Some cases had only a partial medical 
history with the VTH, and the chart of the referral veterinarian was not always available. When 
available, these charts were not always complete or given enough information on the clinical 
signs or medication (name of the drug, dosage). Some of them were also not readable due to the 
handwriting. Importantly, the VTH medical records themselves often lacked important elements, 
especially when the clinician had not included drug allergy in his/her differential diagnosis, 
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despite the fact that multiple elements in the patient’s history and/or its clinical presentation were 
compatible with such ADR. In human medicine it has been clearly demonstrated that the lack of 
completeness and quality of the patient’s chart lead to preventable medical errors.39 
The exact timing between the onset of the reaction and when the drug was originally 
started was not always identified clearly in the medical record, and we were only able to 
calculate this onset for 58.5% of our patients (34 delayed and 4 immediate reactions). Often the 
suspected drug was started by the referral veterinarian who did not provide any timing 
information or his/her notes were not readable. Of the onsets of immediate reactions we were 
able to calculate, the median of 1.5 hours. The onsets we were able to calculate matched those 
reported in human medicine.
16,17
 Interestingly, the median delay for the phenobarbital was longer 
(8 months) like describe in human medicine. Phenobarbital has a much longer half-life than most 
drugs, which delays drug accumulation in patients and could explain the longer period of time 
before the onset of a drug allergic reaction. Two cases with phenobarbital allergy exhibited 
clinical signs compatible with a DRESS reaction, which is often associated with a very long 
delay onset in human medicine.
40
 
In our study, immediate drug allergic reaction represented approximately 15 % of our 
cases compared to 30-40% in human medicine.
9-15
 This discrepancy could represent a true 
difference between dogs and humans. However, we suspect that the proportion of immediate 
reactions was underestimated. Indeed, most medical records of patients seen for anaphylaxis 
have an extremely limited history and do not include any etiology. The exact incidence of 
anaphylaxis in dogs as well as the prevalence of each etiology (insects, plants, drugs, vaccines, 
food) has not yet been studied.
41
 However, an unpublished investigation from our group has been 
able to estimate an incidence of 1.3% of anaphylactic reactions at our teaching hospital over a 
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similar period to the one used in the present retrospective study. This unpublished investigation 
on anaphylaxis included 10.4 % of anaphylaxis linked to a drug, 33.3 % to a vaccine, 13.5 % to 
insects, 5.2% to other chemicals or material exposure, and 37.5 % without known etiology. 
As previously described in human medicine, antibiotics (57.6 %) and NSAIDs (12.1 %) 
were the most commonly suspected drug classes in our study (Table XIV).
11,42
 These two class 
of drugs are the most commonly used in human and veterinary medicine. This could explain the 
higher percentage of reactions. We also showed that antiparasitic drugs were commonly 
associated with drug allergic reactions in our dogs (42.4%). Many dogs receive prophylactic 
antiparasitic therapy on a monthly basis, and this could explain why these drug take the second 
place before NSAIDs if compare with humans. This cannot be directly compared with the 
situation in human medicine as antiparasitics are not commonly used in humans, especially not 
in western countries. As in human medicine, barbiturics and opioids were also implicated in 
many of our cases (10.8% for each).
15
 
To the best of our knowledge, we are the first to report some cases of DRESS in 
veterinary medicine. Our study estimated an incidence of 0.04% for DRESS. This would be 
within the range reported for DRESS in human medicine: 1 case for 1000 or 10,000 of drug 
exposure (0.01-0.1%).
7,43,44
 The mortality rate amongst our DRESS cases was 5%, which 
matches the lower end of the range found in human cases (5-20%).
32,45,46
 It is important to note 
that we identified our cases of DRESS using criteria established in human medicine. These 
criteria may not be directly adaptable to DRESS in dogs. Future work will be required to further 
characterize this syndrome in dogs. The median of 4.5 days for the onset of the reaction after the 
medication was started, is lower than the 7-12 days describe in human medicine.
7,33,47,48
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Also, to the best of our knowledge, the incidence of contact dermatitis in general remains 
undetermined in veterinary medicine. We are the first to report an incidence for contact allergic 
dermatitis associated with drugs in dogs. It is important to note that the common usage of spot-
on preventative drugs in dogs may impact the frequency of drug contact dermatitis compared to 
what is observed in humans, but its incidence in human medicine remains to be established as 
well.  Our data confirm what has been discussed in veterinary review articles, in that, our drug-
induced contact dermatitis were mild and carried out a good prognosis. Therefore, these cases are 
less likely to be seen by a tertiary referral hospital, such as ours, and the incidence of drug 
allergic contact dermatitis might be higher in general private practice. 
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CONCLUSION 
 
This study is the first to estimate an incidence for drug allergic reaction in dogs, as the first to 
report cases of DRESS in dogs, and the first to establish an incidence for drug allergic contact 
dermatitis. The incidence, the clinical pattern, and the drugs involved matched what has been 
described in human medicine. This study also demonstrated a link between early drug 
discontinuation and prognosis as shown in human drug allergy that has already been 
demonstrated in human medicine. The quality and completeness of the medical record were 
important limiting factors. We hope that this study will raise awareness about the risk of drug 
allergy in dogs, but also on the importance of record keeping for both the patient and science. 
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TABLES 
 
TABLE XI: Categories of keywords used for the VDL search  
 
Keyword 
Numberof cases 
found 
General 47 
Liver 641 
Kidney 1364 
Musculoskeletal 30 
Respiratory 378 
Ocular 231 
Cardiovascular 223 
Bone Marrow / blood 518 
Skin & mucocutaneous junction 1305 
CNS 209 
Miscellaneous 275 
Total (with duplicates) 5221 
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Total 2328 
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Table XII: Case population description 
 
  Immediate 
reactions 
Delayed 
reactions 
DRESS Allergic 
Contact 
Dermatitis 
All reactions 
Gender Male: female 7:4 26:29 8:11 4:1 33:33 
Age 
(year, month) 
Median 
(range) 
2y 
(4m-8y11m) 
6y 5m 
(10m-13y1m) 
8y 4m  
(2y-12y) 
1y 6m 
(7m-10y7m) 
6y 
(4m-13y1m) 
Weight 
(kg) 
Median 
(range) 
23.2 
(7-35.4) 
20.2 
(2.7-60.5) 
17.6 
(3.7-40.30) 
35.7 
(8-60.5) 
22.1 
(2.7-60.5) 
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Table XIII: Hospitalizations 
 
  Immediat
e 
reactions 
Delayed 
reactions 
DRESS Allergic 
Contact 
Dermatitis 
All 
reactions 
% of hospitalized 
animals 
 36.4 47.3 47.4 0 45.5 
Hospitalization Duration 
(days) 
Median 
(range) 
0.75 
(0.5-2) 
3 
(0.5-12) 
3 
(0.5-12) 
0 
 
2.5 
(0.5-12) 
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Table XIV: Suspected drugs 
 
Drug 
classes 
Details  Immediate 
reactions 
n (%) 
Delayed 
reactions 
n (%) 
DRESS 
n (%) 
Allergic 
Allergic 
Contact 
Dermatitis 
n (%) 
All 
reactions 
n (%) 
Total   11 (16.7) 55 (83.3) 19 (28.8) 5 (7.6) 65 (100) 
        
Antibiotics   3 (27.3) 34 (54.5) 10 (52.6)  38 (58.4) 
 Cephalosporins 2 14 1  16 (42.1) 
  Cephalexin 1  1  10 
  Cefpodoxime 1    6 
 Beta-lactam  10 5  10 (26.3) 
  Amoxicillin/ 
Clavulanic Acid 
  3  5 
  Amoxicillin/ 
Sulbactam 
  1  2 
  Penicillin   1  2 
  Amoxicillin     1 
 Sulfonamides  4   4 (10.5) 
  Ormetoprim/ 
Sulfadimethoxine 
    1 
  Trimethoprim/ 
Sulfadiazine 
    1 
  Trimethoprim/ 
Sulfamethoxazole 
    1 
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  Unknown Sulfa     1 
 Nitroimadazoles 1 3 1  4 (10.5) 
  Metrinodazole 1  1  4 
 Quinolones   3 2  3 (7.9) 
  Enrofloxacin   2  2 
  Ciprofloxacin     1 
 Lincosamides  1 1  1 (2.6) 
  Clindamycin   1  1 
       
Antiparasitics  4 ( 36.6) 23 (41.8) 2 (10.5) 5 (100) 28 (43.1) 
 Ivermectin/Pyrantel Pamoate 
(Heartgard plus) 
1 6   7 
 Fipronil/(S)-methoprene  5  3 5 
 Selamectin (Revolution)  3  1 3 
 Imidacloprid, Permethrin 
(Advantix) 
 3 1 1 3 
 Unknown heartworm preventative 2    2 
 Spinosad/Milbemycin Oxime 
(Trifexis) 
 1   1 
 Unknown fleas preventative 1    1 
 Milbemycin Oxime (Interceptor)  1   1 
 Spinosad (Comfortis) 1    1 
 Lufenuron   1 1  1 
 Imidacloprid/Permethrin/ 
Pyriproxyfen (Advantix II) 
1   1 
 Fenbendazole/Panacur  1   1 
 Ivermectin   1   1 
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NSAIDs   1 
(9.1) 
7 
(12.7) 
1 (5.3)  8 (12.3) 
 Carprofen  1 4   5 
 Meloxicam   1   1 
 Piroxicam   1   1 
 Deracoxib   1   1 
        
Topicals    7 
(12.7) 
  8 (12.3) 
 Chlorhexidine gluconate 4% spray  2   2 
 Mupirocin (Bactoderm)  1   1 
 Triamcinolone Acetonide spray  1   1 
 Chlorhexidine Gluconate (2%), 
Ketoconazole (1%) Shampoo 
1   1 
 Topical hydrogen peroxide  1   1 
 Antibiotic cream  1   1 
 Nystatin/Neomycin sulfate/Thiostrepton/ 
Triamcinolone acetonide ointment 
1   1 
       
Steroids    7 
(12.7) 
  7 (10.8) 
 Prednisone   3   3 
 Dexamethasone  2   2 
 Trimeprazine/Prednisolone (Temaril-P)  1   1 
 Methylprednisolone acetate  1   1 
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Barbiturics    7 
(12.7) 
2 
(10.5) 
 7 (10.8) 
 Phenobarbital  7 2  7 
       
H1 antagonists   4 
(7.3) 
1   
(5.3) 
 4 (6.2) 
 Diphenhydramine  2 1  2 
 Hydroxyzine  1   1 
 Chlorpheniramine  1   1 
Opioids    3 
(5.4) 
  3  (4.6) 
 Tramadol   3   3 
H2 antagonists   3 
(5.4) 
2 
(10.5) 
 3  (4.6) 
 Famotidine   3 1  3 
Thyroid supplement   2 
(3.6) 
1 (5.3)  2 (3.1) 
 Thyroxine   1 1  1 
 Soloxine   1   1 
Azoles antifungal   2 
(3.6) 
1 (5.3)  2 (3.1) 
 Ketoconazole  2 1  2 
Antiemetics    2 
(3.6) 
  2 (3) 
 Maropitant   1   1 
 Dolasetron   1   1 
Ears medication  1 1   2 (3.1) 
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(9.1) (1.8) 
 Unknown ears medication 1 1   2 
Eyes medication  1 
(9.1) 
   1 (1.5) 
 OTC-eyedrops 1    1 
Gastroprotectant   1 
(1.8) 
  1 (1.5) 
 Sucralfate   1   1 
Onco Chemotherapy   1 
(1.8) 
1 (5.3)  1 (1.5) 
 Masitinib Mesylate  1 1  1 
ACE-inhibitor   1 
(1.8) 
  1 (1.5) 
 Enalapril   1   1 
Diuretic    1 
(1.8) 
  1 (1.5) 
 Furosemide   1   1 
Liver supplement   1 
(1.8) 
  1 (1.5) 
 Denosyl   1   1 
Phenothiazine   1 
(1.8) 
  1 (1.5) 
 Acepromazine  1   1 
Phenypropanolamine   1 
(1.8) 
  1 (1.5) 
Vit K    1 
(1.8) 
  1 (1.5) 
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FIGURE LEGENDS  
 
Figure 9: Case attrition during the review process 
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Figure 10: Clinical signs involved with cases of drug allergy 
Panel A presents the clinical signs observed in patients who suffered from an immediate drug 
allergic reaction among our cohort. Panel B focuses on delayed reactions, with B.1 presenting 
organ systems involved and B.2 the types of blood dyscrasia.  
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CHAPTER 4  
DISCUSSION AND CONCLUSIONS 
 
The World Health Organization defines adverse drug reactions (ADRs) as “noxious, unintended, 
and undesired effect of a drug that occurs at doses used for prevention, diagnosis, or treatment”.  
These ADRs can be classified under two types of events.  Type A reactions (60-80%) are dose 
dependent, predictable, and directly related to pharmacology/chemical properties. Type B 
reactions (20-40%) are not dose dependent, non-predictable, and if immune-mediated are called 
“drug hypersensitivity” or “drug allergy.1-8 These later reactions are further separated into two 
categories: immediate (anaphylactic) or delayed reactions. 
In human medicine, adverse drug reactions in general are the 4
th
-6
th
 cause of death.
9,10
 
They affect 10-20% of the hospitalized patients and 7% of general population.
7,9,11-15
 The annual 
cost of these reactions, including treatment of the primary reactions, complications, and 
increased length of hospitalization is estimate to $500 billion in the United States.
9,16
 
Drug hypersensitivity reactions are thought to account for 1/3 of all ADRs and are 
thought to affect 0.2 -3% for the general patient population, and potentially up to 15-20% of 
hospitalized patients.
17-23
 In veterinary medicine, the incidence of drug allergic reaction has 
never been investigated. However, drug allergy experts believe it is similar to what is observed 
in humans when considering veterinary patients such as dogs who often receive similar drugs for 
similar diseases than their human counterpart.
24
 
In human medicine, clinicians’ lack of awareness and knowledge about drug allergy has 
been shown to affect incidence estimations, but also the prognosis of these reactions.
2,6,25-28
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Thus, the present thesis aim to better understand the impact of drug allergy in veterinary 
medicine, by characterizing these reactions and their incidence in dogs, and evaluating the 
awareness amongst veterinarians on the subject.  
The survey suggests that there might be a lack of awareness secondary to a lack of 
teaching specific to drug allergy in veterinary medicine, like has been identified in human 
medicine previously. Interestingly, For 16.3% of the “likely” and more than half of the 
“possible” (58.3%) drug allergic reactions identified in our retrospective study, a drug allergy 
was not mentioned at all in the medical record. Furthermore, only 38.5% of these cases had a 
drug allergy formerly included in differential diagnosis reported in the patient’s medical record.  
Both studies therefore reinforce the possibility that lack of awareness could have decreased the 
incidence of allergic reactions we found in dogs during the retrospective study.   
Other data further suggest a lack of awareness or knowledge about drug allergy among 
veterinarians. Thus, 83.1% of the survey responders indicated only clinical signs matching 
anaphylaxis (e.g. angioedema, urticaria, respiratory distress) and 1.0% indicated only clinical 
signs matching delayed reactions (e.g. Erythema Multiforme, Stephen Johnson Syndrome, ITP, 
IMHA) (figure 6A, table I-IV). Yet, in human medicine, immediate reactions are thought to 
account for 20-40% of all drug hypersensitivity reactions. In addition, “immediate” reactions 
represented only 16.7% of all the selected drug allergic reactions. Interestingly, survey 
participants significantly increased their estimate of drug allergy cases they see per year after 
reading our short informative paragraph on the subject. 
In human medicine the lack of training was identified as a cause of non-recognition of 
drug allergy cases, leading to poor management and outcome.
29
 The impact of an educational 
initiative on drug allergy was found to have a positive impact and the diagnosis and management 
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of drug allergy in a tertiary care medical center.
30
 Interestingly, data of our survey showed that 
43.8% (116) of the responders did not feel confident in recognizing and treating drug allergic 
reactions. Half of the participants also indicated that the information about drug allergy in the 
veterinary literature is insufficient. It is possible that the lack of recognition of a possible or 
likely drug allergy in multiple cases of our retrospective study (eliminated before, or kept for, the 
final characterization) is also related to an inadequate training about drug allergy during school 
and/or continuing education for the clinicians involved with these cases. Interestingly, there is no 
specific requirement from the AVMA for training about drug allergy in the US veterinary school. 
Amongst the participants, 87.7% indicated being interested in learning more about drug allergy 
as part of their continuing education (national or regional conferences (63.3%); in-house or 
university seminars (52.3%); journal articles (62.4%); or online (49%; e.g. webinars or 
Veterinary Internet Network, VIN)).  
In the survey, 79.9% of the responders indicated that their medical record system include 
a warning system if a patient had a history of suspected or confirmed drug allergic reaction, 
nevertheless 22.3% of the participants “never” ask and 43.7% “sometimes” ask about previous 
drug allergy when taking their patient’s history. In addition, 13.4% of participants indicated that 
they “never” warn and 48.7% “sometimes” warn the owners about drug allergic reaction when 
prescribing a drug to a patient. Yet, antibiotics, antiparasitics and NSAIDs are the most 
commonly prescribed drugs in veterinary and they were the most commonly associated with the 
drug allergic reactions studied in our retrospective study. The risk of drug allergy among dogs is 
therefore significant.  
It is noteworthy that about 40 % of the preselected cases during the database searches of 
our retrospective study had to be eliminated for lack of critical information in the medical record 
107 
 
(e.g. pre-exposure to the culprit drug). Interestingly, such critical information was also missing 
for certain cases that had been fully followed within our hospital. When suspecting a drug 
allergic reaction, a thorough review of the patient’s past history (e.g. previous reactions; previous 
drug exposure; concurrent immune disorder) and details of the reaction itself (e.g. timing, 
evolution, clinical signs) is critical to the diagnosis. In human medicine, the reporting of drug 
allergy in the medical record and the quality and completeness of the medical record has been 
shown to reduce the number of medical errors.
31
 
In conclusion, this thesis identified a lack of awareness towards drug allergy in veterinary 
medicine, leading to poor recognition of these reaction and therefore poor management. This 
work also confirmed that drug allergic reactions are potentially as frequent in dogs as they are in 
human medicine, in addition to sharing very similar clinical patterns.  We therefore think that 
improving education of veterinarians on the subject could have a significant impact: 1) it should 
improve diagnosis and management of drug allergy cases; 2) it should improve the determination 
of a more accurate incidence of drug allergy in veterinary patients; 3) #2 should improve funding 
of research on veterinary drug allergy; #3 should improve #1.  In the meanwhile, more research, 
such as a prospective study, will be needed to better understand the impact of the drug allergic 
reactions in veterinary medicine, and eventually create guidelines to improve diagnosis and 
management of these reactions.  
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APPENDIX 
Page 1
Drug allergy in veterinary medicine<br>
 
 
College of Veterinary Medicine 
Department of Comparative Biosciences 
2001 South Lincoln Avenue 
Urbana IL 61802 
 
 
Dear Colleague, 
 
You can help us advance veterinary medicine.  
 
Our laboratory at UIUC studies drug allergy in both human and veterinary patients. However, to date, very little is known 
about these reactions in veterinary medicine. The present survey is one of our ongoing projects to improve the lack of 
knowledge on this subject.  
 
The survey should not take more than 15 minutes and your name will remain confidential in the analysis of any 
information regarding this study. Survey information will be combined from all participants and be reported in aggregate, 
only. Your name will not be associated in any presentation or publication of the results. 
 
Thank you in advance for your participation. 
 
Sincerely, 
 
Drs Sidonie Lavergne & Fabrice Fosset 
This survey is only focused on drug allergy in veterinary medicine. 
 
If you are interrupted during the survey, do not worry, you will be able to take where you left easily. Indeed, 
SurveyMonkey will have saved your previous answers and will automatically bring you back where you left. 
 
During the survey, you will only be able to navigate forward, so take your time before moving on to the next question. This 
feature allow a higher quality of the output. 
 
Please focus your answers on your own individual experience rather than your clinics's situation. 
 
You will have the option to skip questions, but please, answer as many questions as possible. 
 
Thanks again for helping us! 
 
 
 
 
Instructions
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1. Did you obtain your DVM degree from the University of Illinois College of Veterinary 
Medicine?
Thanks for your participation! 
 
If you did not graduate from UIUC, you received this survey by accident.  
This preliminary study is limited to UIUC graduates. We hope to extend it next year to other DVMs.  
Hopefully, you will be interested in participating then as well. 
 
For more information on drug allergy in veterinary medicine, here are some references: 
 
Drug hypersensitivity reactions targeting the skin in dogs and cats. 
Voie KL, Campbell KL, Lavergne SN  
J Vet Intern Med 2012;26(4):863­74 
 
Nephrotic syndrome associated with administration of sulfadimethoxine/ormetoprim in a Doberman. 
Vasilopulos RJ, Mackin A, Lavergne SN, Trepanier LA 
J Small Anim Pract. 2005;46(5):232­6 
 
Have a nice day. 
 
Drs Sidonie Lavergne & Fabrice Fosset 
 
 
2. When did you graduate from veterinary school?
3. Please indicate your year of birth? 
 
 
year
Year of graduation 6
 
Year
Year of birth 6
Yes
 
nmlkj
No
 
nmlkj
Yes, but I did not follow my whole DVM training at UIUC before obtaining my diploma.
 
nmlkj
If you did not graduate between 1974 and 2014, please specify? 
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4. Please identify your gender? 
5. Are you a Board Certified Specialist or in training?
6. Please specify the specialty.
7. Indicate whether you have pursued, or pursuing, a degree in research.
 
 
Board Certified 6
Residency Trained 6
Intern 6
Resident 6
Fellow 6
 
 
female
 
nmlkj
male
 
nmlkj
Yes
 
nmlkj
No
 
nmlkj
Other (please specify) 
PhD
 
gfedc
Thesis Master
 
gfedc
Non­Thesis Master
 
gfedc
None of the above
 
gfedc
Other (please specify) 
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8. Are you presently working in the United States of America? 
9. Since you received your DVM degree, what professional environment have you been 
involved with? 
Please, indicate the number of years for each applicable environment. 
10. As a clinician, what species do you see, or used to see, the most in consultation? 
Please indicate a percentage if more than one category. 
 
States
Yes (Please specify) 6
 
number of years
Private practice 6
Academia/research 6
Academia/clinic 6
Industry 6
Government (e.g. FDA; 
EPA…)
6
 
Percentage
Equine 6
Food animals 6
Dogs and/or cats 6
Exotics/Zoo/Wildlife 6
 
If you working outside of the US, please specify here? 
Other (please specify with # of years) 
Other (please specify with %) 
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11. Have you attended a lecture, laboratory, discussion, or school seminar about drug 
allergy during your DVM training at the UIUC College of Veterinary Medicine?
12. Do you feel that the information regarding drug allergy in your veterinary curriculum 
is/was sufficient for you to diagnose and treat drug allergic reactions with confidence?
13. Since graduation, have you attended a presentation about drug allergy?
14. Since graduation, have you read article(s) about drug allergy?
15. Do you remember the name of journal or the title of the article(s)?
 
 
 
 
5
6
 
Yes
 
nmlkj
No
 
nmlkj
I do not remember
 
nmlkj
Yes
 
nmlkj
No
 
nmlkj
I do not know
 
nmlkj
Does not apply (I am not and was never a practicing clinician.)
 
nmlkj
No
 
nmlkj
Yes
 
nmlkj
If yes, please specify (e.g. conference seminar; conference lecture; academic seminar series) 
Yes
 
nmlkj
No
 
nmlkj
I don't remember
 
nmlkj
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16. Do you feel that the information about drug allergy in the veterinary literature is 
sufficient?
17. Since graduation have you ever worked as a clinician?
18. How often do you usually include “drug allergy” or “drug allergic reaction” in your 
differential diagnosis?  
­ If you are not practicing anymore, address the question for when you used to be in 
clinics. ­
19. How many confirmed or highly suspicious cases of drug allergy do you see per year 
(on average)? 
­ If you are not practicing anymore, address the question for when you used to be in 
clinics. ­
 
 
Yes
 
nmlkj
No
 
nmlkj
I do not know
 
nmlkj
Yes
 
nmlkj
No
 
nmlkj
Never (none of your patients)
 
nmlkj
Sometimes (1­25% of your patients)
 
nmlkj
Regularly (26­50% of your patients)
 
nmlkj
Often (51­75% of your patients)
 
nmlkj
Almost always (76­100% of your patients)
 
nmlkj
Always (all of your patients)
 
nmlkj
None
 
nmlkj
1 to 12
 
nmlkj
13 to 24
 
nmlkj
25 to 60
 
nmlkj
> 60
 
nmlkj
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20. When you take the history of a patient, do you or your technician ask specifically 
whether this patient has any known drug allergy? 
­ If you are not practicing anymore, address the question for when you used to be in 
clinics. ­
21. When prescribing a medication to a patient, are you warning the owner(s) specifically 
about the risk of allergic drug reaction? 
­ If you are not practicing anymore, address the question for when you used to be in 
clinics. ­
22. Does your medical record system have a warning system in place when a patient had a 
previous, suspected or confirmed, drug allergic reaction (e.g. sticker, tag, alert message in 
the electronic system)? 
­ If you are not practicing anymore, address the question for when you used to be in 
clinics. ­
23. Please indicate the clinical signs that you might associate with a drug allergic 
reaction?
 
 
5
6
Never
 
nmlkj
Sometimes
 
nmlkj
Most of the time
 
nmlkj
Always
 
nmlkj
Never
 
nmlkj
Sometimes
 
nmlkj
Most of the time
 
nmlkj
Always
 
nmlkj
Yes
 
nmlkj
No
 
nmlkj
I don’t know
 
nmlkj
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24. Please indicate the blood work abnormalities that you might associate with a drug 
allergic reaction.
 
25. Select in the list bellow the organ systems that may be targeted during a drug allergic 
reaction.
A drug allergic reaction is an antigen­specific immune reaction that targets a drug or a protein modified by a drug. Such 
drug allergic reaction requires a prior exposure to the drug (of at least a few days). Once the immune system is 
sensitized against the drug, the allergic reaction can be immediate (< 24h after drug exposure) or delayed (> a few days 
or weeks or months of drug exposure). Clinical signs associated with a drug allergic reaction commonly involve the skin, 
the blood cells, and the liver. However, kidneys, respiratory organs, and other digestive organs can also be affected. 
Depending on the exact pathological mechanisms, any other organ could be involved (e.g. brain and vasculitis). The 
diagnosis is usually based on the clinical presentation and the medical history. However, some diagnostic tests, such as 
tissue biopsies or drug­specific immune tests (e.g. basophil activation test; lymphocyte transformation test) can be 
conducted.  
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After the following short paragraph on drug allergies, a few more questions...
 
Cardiovascular
 
gfedc
Respiratory
 
gfedc
Nervous
 
gfedc
Skin
 
gfedc
Musculoskeletal
 
gfedc
Blood (including bone marrow)
 
gfedc
Digestive (including liver)
 
gfedc
Endocrine (excluding reproductive organs)
 
gfedc
Urinary (excluding reproductive organs)
 
gfedc
Reproductive
 
gfedc
None of the above
 
gfedc
I am not sure
 
gfedc
Other (please specify) 
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26. Are you currently working as a clinician?
27. After reading the previous short paragraph on drug allergy, would you change how 
often you usually include "drug allergy" in your differential diagnosis?  
­ If you are not practicing anymore, address the question for when you used to be in 
clinics. ­
28. After reading the previous short paragraph on drug allergy, would you change how 
many confirmed or highly suspicious cases of drug allergy do you see per year (on 
average)? 
­ If you are not practicing anymore, address the question for when you used to be in 
clinics. ­ 
 
29. After reading the previous short paragraph on drug allergy, how many confirmed or 
highly suspicious cases of drug allergy do you see per year (on average)? 
­ If you are not practicing anymore, address the question for when you used to be in 
clinics. ­ 
 
 
Yes
 
nmlkj
Not anymore
 
nmlkj
I never worked as a clinician.
 
nmlkj
Yes
 
nmlkj
No
 
nmlkj
Maybe
 
nmlkj
Yes
 
nmlkj
No
 
nmlkj
None
 
nmlkj
1 to 12
 
nmlkj
13 to 24
 
nmlkj
25 to 60
 
nmlkj
> 60
 
nmlkj
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30. After reading the previous short paragraph on drug allergy, would you start asking 
whether your patient has any known drug allergy?
31. After reading the previous short paragraph about drug allergy, would you start warning 
the owner(s) specifically about the risk of drug allergy before prescribing a drug?
32. Would you be interested in learning more about drug allergy as part of your continuing 
education?
33. How you would like to get more information on drug allergy?
 
 
 
Yes
 
nmlkj
No
 
nmlkj
I already do it
 
nmlkj
Do not apply to me
 
nmlkj
Never
 
nmlkj
Sometimes
 
nmlkj
Most of the time
 
nmlkj
Always
 
nmlkj
I already do it
 
nmlkj
Do not apply to me
 
nmlkj
Yes
 
nmlkj
No, I am not interested in learning more about drug allergy.
 
nmlkj
I do not take any continuing education training in general.
 
nmlkj
National or regional conference
 
gfedc
Seminars (in house, University…)
 
gfedc
Journal articles
 
gfedc
Webinar
 
gfedc
Other (please specify) 
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34. Would you consider consulting with a veterinarian specialized in drug allergy for 
specific cases (past, present or future)?
35. Feel free to leave any comments or suggestions here.
 
For more information or consultation, please email Dr. Sidonie Lavergne 
(slavergn@illinois.edu). 
 
For more information on drug allergy in veterinary medicine, here are some references: 
 
Drug hypersensitivity reactions targeting the skin in dogs and cats. 
Voie KL, Campbell KL, Lavergne SN  
J Vet Intern Med 2012;26(4):863­74 
 
Nephrotic syndrome associated with administration of sulfadimethoxine/ormetoprim in a Doberman. 
Vasilopulos RJ, Mackin A, Lavergne SN, Trepanier LA 
J Small Anim Pract. 2005;46(5):232­6 
 
Thanks again and have a nice day! 
 
Drs Sidonie Lavergne & Fabrice Fosset 
 
 
 
Suggestions and Comments
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Thanks for your participation!
Yes
 
nmlkj
No
 
nmlkj
Not applicable
 
nmlkj
